Table 3.

Cost-effectiveness analysis results

	CAD or PAD			PAD only			CAD only
	RIV + ASA	ASA	Δ	RIV + ASA	ASA	Δ	RIV + ASA	ASA	Δ
Cost category (€)
Drug costs	9.391	200	9.191	9.047	188	8.859	9.379	200	9.180
Direct health costs	9.252	12.659	− 3.407	14.418	18.962	− 4.544	8.538	11.395	− 2.857
Total cost	18.643	12.858	5.785	23.465	19.150	4.315	17.917	11.594	6.323
Outcome
QALYs, per patient	9.62	9.27	0.35	8.67	8.14	0.54	9.70	9.36	0.34
	RIV + ASA vs. ASA			RIV + ASA vs. ASA			RIV + ASA vs. ASA
ICER	Incremental costs (€)	Incremental effectiveness	Incremental ratio (€)	Incremental costs (€)	Incremental effectiveness	Incremental ratio (€)	Incremental costs (€)	Incremental effectiveness	Incremental ratio (€)
Cost per QALY	5.785	0.35	16.522	4.315	0.54	8.003	6.323	0.34	18.599
	CAD and PAD			CAD with CKD			CAD with HF
	RIV + ASA	ASA	Δ	RIV + ASA	ASA	Δ	RIV + ASA	ASA	Δ
Cost category (€)
Drug costs	8.877	183	8.694	7.913	165	7.748	8.734	179	8.555
Direct health costs	13.408	16.408	− 3.000	10.060	12.294	− 2.234	7.634	10.049	− 2.415
Total cost	22.285	16.591	5.694	17.972	12.459	5.513	16.367	10.228	6.139
Outcome
QALYs, per patient	8.63	8.07	0.56	7.76	7.34	0.43	8.70	8.08	0.62
	RIV + ASA vs. ASA			RIV + ASA vs. ASA			RIV + ASA vs. ASA
ICER	Incremental costs (€)	Incremental effectiveness	Incremental ratio (€)	Incremental costs (€)	Incremental effectiveness	Incremental ratio (€)	Incremental costs (€)	Incremental effectiveness	Incremental ratio (€)
Cost per QALY	5.694	0.56	10.199	5.513	0.43	12.971	6.139	0.62	9.905

All costs are reported in Euros (€)

Delta symbol defines the difference between information (costs, QALYs and ICERs) for RIV+ASA vs. ASA alone

CAD coronary artery disease, PAD peripheral artery disease, CKD chronic kidney disease, HF heart failure, RIV rivaroxaban, ASA aspirin, QALY quality-adjusted life-year, ICER incremental cost-effectiveness ratio